Press releases
-
-
-
-
Internal link ProQR traite le premier patient dans l’essai STELLAR de Phase 1/2 du QR-421a pour le syndrome d’Usher de type 2
-
Internal link ProQR Doses First Patient in Phase 1/2 STELLAR Trial of QR-421a for Usher Syndrome Type 2
-
Internal link ProQR to Present at Cowen Health Care Conference
-
-
-
-
Internal link ProQR to Host R&D Day in New York on January 29
-
-
-
Internal link ProQR Receives Orphan Drug Designation from EMA for Drug Candidate QR-313 for Dystrophic Epidermolysis Bullosa
-
-
Internal link ProQR Announces Results for the Third Quarter of 2017
-
-
-
Internal link ProQR Doses First LCA 10 Patient in Clinical Trial of QR-110, ProQR’s Lead Program for Genetic Blindness
-
-
Internal link ProQR to Present at EuroTIDES Conference
-
Internal link ProQR Announces Management Change and Key Promotions
-
Internal link ProQR Announces Presentations and Investor & Analyst Event at the North American Cystic Fibrosis Conference
-
-
Internal link ProQR Announces Positive Top-Line Results from a Phase 1b Study of QR-010 in Subjects with Cystic Fibrosis
-
Internal link ProQR Presents in vivo Proof of Concept Data for the Axiomer® RNA Editing Platform Technology